Suit Puts Focus On Advisory Panel Consensus-Building

A recent legal flap that may force the National Academy of Sciences (NAS) to open the proceedings of its advisory committees to public scrutiny has focused the attention of researchers and government officials on how advisory panels produce reports. NAS-through its operating arm, the National Research Council (NRC)-is frequently called on to give status reports on various scientific and medical issues and policies, as are advisory panels convened by other agencies. The resulting reports frequen

Written bySteven Benowitz
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

A recent legal flap that may force the National Academy of Sciences (NAS) to open the proceedings of its advisory committees to public scrutiny has focused the attention of researchers and government officials on how advisory panels produce reports. NAS-through its operating arm, the National Research Council (NRC)-is frequently called on to give status reports on various scientific and medical issues and policies, as are advisory panels convened by other agencies. The resulting reports frequently help resolve scientific disputes, gauge the status of research disciplines, examine standards of care, and influence policy and funding decisions.

DO YOUR DUTY: UC-Santa Cruz’s M.R.C. Greenwood believes it’s a scientist’s responsibility to participate in national committees that produce reports. Because of the potential impact government advisory panels may have, Congress passed the 1972 Federal Advisory Committee Act (FACA). The act states that panels formed to advise the federal government must open their proceedings to ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies